San Diego-based BioLegend Inc. acquired the shares of Covance Antibody Services Inc., a business unit of Massachusetts-based Covance Inc., on August 29.

The Covance Antibody business unit develops and manufactures antibodies and research reagents for neuroscience, immunopathology, cell biology, epitope tags, and immunohistochemistry detection. These products are meant to complement and enhance the current selection of BioLegend research reagents.

"We are excited to add Covance Antibody's people and products to the BioLegend team," said Gene Lay, president and CEO of BioLegend.

As neuroinflammation and neurodegeneration become increasingly important topics, Covance Antibody is a strategic fit in BioLegend's commitment to the advancement of discovery in neuroscience, Lay said.

"The addition of Neuroscience and IHC antibody tools to our catalog means accelerated discovery for our current and new customers. We also hope to bring our well-known quality, support, and value in the Immunology community to Neuroscience researchers world-wide," said Lay.

BioLegend manufactures antibodies and reagents for biomedical research. The product portfolio includes flow cytometry, cell biology, and functional reagents for research in immunology, cancer research and stem cells.